

Citations

1. Brekhman II, Dardymov IV. New substances of plant origin which increase nonspecific resistance. *Annu Rev Pharmacol* 1969;9:419-430.
2. Panossian A, Wikman G, Wagner H. Plant adaptogens. III. Earlier and more recent aspects and concepts on their mode of action. *Phytomedicine* 1999;6:287-300.
3. Wagner H, Norr H. Plant adaptogens. *Phytomedicine* 1994;1:63-76.
4. WHO. Radix Ginseng. WHO Monographs on Selected Medicinal Plants. 1 vol. Geneva: World Health Organization; 1999:168-182.
5. BHMA. Ginseng. In: Bradley P, ed. *British Herbal Compendium*. Bournemouth, UK: British Herbal Medical Association; 1992:115-117.
6. ESCOP. Radix Ginseng. ESCOP Monographs: the Scientific Foundation for Herbal Medicinal Products. 2nd ed. Exeter, UK: European Scientific Cooperative on Phytotherapy and Thieme; 2003:211-225.
7. McKenna DJ, Jones K, Hughes K, Humphrey S. Ginseng. *Botanical Medicines*. 2nd ed. Binghamton, NY: Haworth Press; 2002:505-546.
8. Court WE. Ginseng, the Genus *Panax* (Medicinal and Aromatic Plants, Industrial Profiles). London: Taylor and Francis; 2000.
9. Bensky D, Clavey S, Stöger E, Gamble A. Ren Shen. *Chinese Herbal Medicine: Materia Medica*. 3rd ed. Seattle: Eastland Press; 2004:710-714.
10. Chen J, Chen T. Ren Shen (Radix Ginseng). *Chinese Medical Herbology and Pharmacology*. City of Industry, Calif: Art of Medicine Press Inc; 2004:836-840.
11. Harkey MR, Henderson GL, Gershwin ME et al. Variability in commercial ginseng products: an analysis of 25 preparations. *Am J Clin Nutr* 2001;73:1101-1106.
12. Chang YS, Seo EK, Gyllenhaal C, Block KI. *Panax ginseng*: a role in cancer therapy? *Integr Cancer Ther* 2003;2:13-33.
13. Block KI, Mead MN. Immune system effects of echinacea, ginseng, and astragalus: a review. *Integr Cancer Ther* 2003;2:247-267.
14. Coon JT, Ernst E. *Panax ginseng*: a systematic review of adverse effects and drug interactions. *Drug Saf* 2002;25:323-344.
15. Blumenthal M, Busse W, Goldberg A et al. *The Complete German Commission E Monographs*. Austin, Texas: American Botanical Council: Integrative Medicine Communications; 1998.
16. Shibata S, Tanaka O, Shoji J, Saito H. Chemistry and pharmacology of *Panax*. In: Wagner H, Hikomo H, Farnsworth NR, eds. *Economic and Medicinal Plant Research*. 1 vol. New York: Academic Press; 1985:217-284.
17. Odashima S, Ohta T, Kohno H, et al. Control of phenotypic expression of cultured B16 melanoma cells by plant glycosides. *Cancer Res* 1985;45:2781-2784.
18. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. *Biochem Pharmacol* 1999;58:1685-1693.
19. Sengupta S, Toh SA, Sellers LA et al. Modulating angiogenesis: the yin and the yang in ginseng. *Circulation* 2004;110:1219-1225.
20. Yance DR, Jr., Sagar SM. Targeting angiogenesis with integrative cancer therapies. *Integr Cancer Ther* 2006;5:9-29.
21. Ling C, Li Y, Zhu X et al. Ginsenosides may reverse the dexamethasone-induced down-regulation of glucocorticoid receptor. *Gen Comp Endocrinol* 2005;140:203-209.
22. Park MT, Cha HJ, Jeong JW et al. Glucocorticoid receptor-induced down-regulation of MMP-9 by ginseng components, PD and PT, contributes to inhibition of the invasive capacity of HT1080 human fibrosarcoma cells. *Mol Cells* 1999;9:476-483.
23. Chan RY, Chen WF, Dong A et al. Estrogen-like activity of ginsenoside Rg1 derived from *Panax notoginseng*. *J Clin Endocrinol Metab* 2002;87:3691-3695.
24. Kinyamu HK, Archer TK. Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in MDM2 protein expression. *Mol Cell Biol* 2003;23:5867-5881.
25. Lee YJ, Jin YR, Lim WC et al. Ginsenoside-Rb1 acts as a weak phytoestrogen in MCF-7 human breast cancer cells. *Arch Pharm Res* 2003;26:58-63.
26. Lee Y, Jin Y, Lim W et al. A ginsenoside-Rh1, a component of ginseng saponin, activates estrogen receptor in human breast carcinoma MCF-7 cells. *J Steroid Biochem Mol Biol* 2003;84:463-468.
27. Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. *Drug Metab Dispos* 2003;31:533-539.
28. Anderson GD, Rosito G, Mohutsy MA, Elmer GW. Drug interaction potential of soy extract and *Panax ginseng*. *J Clin Pharmacol* 2003;43:643-648.
29. Gurley BJ, Gardner SF, Hubbard MA et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. *Clin Pharmacol Ther* 2002;72:276-287.

Citations and Reference Literature: Ginseng

30. Chang TK, Chen J, Benetton SA. In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. *Drug Metab Dispos* 2002;30:378-384.
31. Henderson GL, Harkey MR, Gershwin ME et al. Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. *Life Sci* 1999;65:PL209-214.
32. Yu CT, Chen J, Teng XW et al. Lack of evidence for induction of CYP2B1, CYP3A23, and CYP1A2 gene expression by Panax ginseng and Panax quinquefolius extracts in adult rats and primary cultures of rat hepatocytes. *Drug Metab Dispos* 2005;33:19-22.
33. See reference 32.
34. Lee HC, Hwang SG, Lee YG et al. In vivo effects of Panax ginseng extracts on the cytochrome P450-dependent monooxygenase system in the liver of 2,3,7,8-tetrachlorodibenzo-p-dioxin-exposed guinea pig. *Life Sci* 2002;71:759-769.
35. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. *Drug Metab Rev* 2004;36:57-104.
36. Hasegawa H, Sung JH, Matsumiya S et al. Reversal of daunomycin and vinblastine resistance in multidrug-resistant P388 leukemia in vitro through enhanced cytotoxicity by triterpenoids. *Planta Med* 1995;61:409-413.
37. Lee SJ, Sung JH, Moon CK, Lee BH. Antitumor activity of a novel ginseng saponin metabolite in human pulmonary adenocarcinoma cells resistant to cisplatin. *Cancer Lett* 1999;144:39-43.
38. Choi CH, Kang G, Min YD. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. *Planta Med* 2003;69:235-240.
39. Kim SW, Kwon HY, Chi DW et al. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3). *Biochem Pharmacol* 2003;65:75-82.
40. You JS, Huang HF, Chang YL. Panax ginseng reduces Adriamycin-induced heart failure in rats. *Phytother Res* 2005;19:1018-1022.
41. Hasegawa H. Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. *J Pharmacol Sci* 2004;95:153-157.
42. Bae EA, Han MJ, Kim EJ, Kim DH. Transformation of ginseng saponins to ginsenoside Rh2 by acids and human intestinal bacteria and biological activities of their transformants. *Arch Pharm Res* 2004;27:61-67.
43. Scaglione F, Weiser K, Alessandria M. Effects of the standardised ginseng extract G115 in patients with chronic bronchitis: a nonblinded, randomised, comparative pilot study. *Clin Drug Invest* 2001;21:41-45.
44. Gao R, Jin J, Niu Y. [Potentiated effects of total saponins of Panax ginseng on inhibition of leukemic cells by cytotoxic drugs]. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 1999;19:17-19.
45. Jin XC, Sun JZ, Wang X. [Effects of xinshuakang granule on cardiac function and atrial natriuretic polypeptide levels in rabbits with experimental congestive heart failure]. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 1996;16:424-426.
46. Kang J, Lee Y, No K et al. Ginseng intestinal metabolite-I (GIM-I) reduces doxorubicin toxicity in the mouse testis. *Reprod Toxicol* 2002;16:291-298.
47. Tong CN, Matsuda H, Kubo M. [Pharmacological study on Panax ginseng C. A. Meyer. XV. Effects of 70% methanolic extract from red and white ginseng on the antitumor activity of mitomycin C]. *Yakugaku Zasshi* 1992;112:856-865.
48. Kubo M, Tong CN, Matsuda H. Influence of the 70% methanolic extract from red ginseng on the lysosome of tumor cells and on the cytotoxic effect of mitomycin C. *Planta Med* 1992;58:424-428.
49. Matsuda H, Tong CN, Kubo M. [Pharmacological study on Panax ginseng C. A. Meyer. XIV. Effect of 70% methanolic extract from red ginseng on the cytotoxic effect of mitomycin C against rat ascites hepatoma AH 130]. *Yakugaku Zasshi* 1992;112:846-855.
50. Tode T, Kikuchi Y, Sasa H et al. [In vitro and in vivo effects of ginsenoside Rh2 on the proliferation of serous cystadenocarcinoma of the human ovary]. *Nippon Sanka Fujinka Gakkai Zasshi* 1992;44:589-594.
51. Lee SJ, Ko WG, Kim JH et al. Induction of apoptosis by a novel intestinal metabolite of ginseng saponin via cytochrome c-mediated activation of caspase-3 protease. *Biochem Pharmacol* 2000;60:677-685.
52. Shin HJ, Kim YS, Kwak YS et al. Enhancement of antitumor effects of paclitaxel (Taxol) in combination with red ginseng acidic polysaccharide (RGAP). *Planta Med* 2004;70:1033-1038.
53. Kim SH, Cho CK, Yoo SY et al. In vivo radioprotective activity of Panax ginseng and diethyldithiocarbamate. *In Vivo* 1993;7:467-470.
54. Takeda A, Katoh N, Yonezawa M. Restoration of radiation injury by ginseng. III. Radioprotective effect of thermostable fraction of ginseng extract on mice, rats and guinea pigs. *J Radiat Res (Tokyo)* 1982;23:150-167.
55. Yonezawa M, Katoh N, Takeda A. Restoration of radiation injury by ginseng. II. Some properties of the radioprotective substances. *J Radiat Res (Tokyo)* 1981;22:336-343.
56. Cao RM, Liu C, Lin M et al. [Radioprotective effect of water-soluble nonsaponin components in ginseng]. *Zhongguo Zhong Yao Za Zhi* 1991;16:433-434, 448 proceeding.
57. Xie FY, Zeng ZF, Huang HY. [Clinical observation on nasopharyngeal carcinoma treated with combined therapy of radiotherapy and ginseng polysaccharide injection]. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2001;21:332-334.

Citations and Reference Literature: Ginseng

58. Lee TK, Johnke RM, Allison RR et al. Radioprotective potential of ginseng. *Mutagenesis* 2005;20:237-243.
59. Lee HJ, Kim SR, Kim JC et al. In vivo radioprotective effect of *Panax ginseng* C.A. Meyer and identification of active ginsenosides. *Phytother Res* 2006;20:392-395.
60. Yun YS, Moon HS, Oh YR et al. Effect of red ginseng on natural killer cell activity in mice with lung adenoma induced by urethan and benzo(a)pyrene. *Cancer Detect Prev Suppl* 1987;1:301-309.
61. Suh SO, Kroh M, Kim NR et al. Effects of red ginseng upon postoperative immunity and survival in patients with stage III gastric cancer. *Am J Chin Med* 2002;30:483-494.
62. Zee-Cheng RK. Shi-quan-da-bu-tang (ten significant tonic decoction), SQT: a potent Chinese biological response modifier in cancer immunotherapy, potentiation and detoxification of anticancer drugs. *Methods Find Exp Clin Pharmacol* 1992;14:725-736.
63. Lee FC, Ko JH, Park JK, Lee JS. Effects of *Panax ginseng* on blood alcohol clearance in man. *Clin Exp Pharmacol Physiol* 1987;14:543-546.
64. Lee YJ, Pantuck CB, Pantuck EJ. Effect of ginseng on plasma levels of ethanol in the rat. *Planta Med* 1993;59:17-19.
65. Koo MW. Effects of ginseng on ethanol-induced sedation in mice. *Life Sci* 1999;64:153-160.
66. Lee SC, Moon YS, You KH. Effects of red ginseng saponins and nootropic drugs on impaired acquisition of ethanol-treated rats in passive avoidance performance. *J Ethnopharmacol* 2000;69:1-8.
67. Okamura N, Kobayashi K, Akaike A, Yagi A. Protective effect of ginseng saponins against impaired brain growth in neonatal rats exposed to ethanol. *Biol Pharm Bull* 1994;17:270-274.
68. Rudakewich M, Ba F, Benishin CG. Neurotrophic and neuroprotective actions of ginsenosides Rb(1) and Rg(1). *Planta Med* 2001;67:533-537.
69. Chen XC, Zhu YG, Zhu LA et al. Ginsenoside Rg1 attenuates dopamine-induced apoptosis in PC12 cells by suppressing oxidative stress. *Eur J Pharmacol* 2003;473:1-7.
70. Ramarao P, Bhargava HN. Antagonism of the acute pharmacological actions of morphine by *Panax ginseng* extract. *Gen Pharmacol* 1990;21:877-880.
71. Bhargava HN, Ramarao P. The effect of *Panax ginseng* on the development of tolerance to the pharmacological actions of morphine in the rat. *Gen Pharmacol* 1991;22:521-525.
72. Kim HS, Kang JG, Seong YH et al. Blockade by ginseng total saponin of the development of cocaine-induced reverse tolerance and dopamine receptor supersensitivity in mice. *Pharmacol Biochem Behav* 1995;50:23-27.
73. Kim HS, Hong YT, Jang CG. Effects of the ginsenosides Rg1 and Rb1 on morphine-induced hyperactivity and reinforcement in mice. *J Pharm Pharmacol* 1998;50:555-560.
74. Kim HS, Hong YT, Oh KW et al. Inhibition by ginsenosides Rb1 and Rg1 of methamphetamine-induced hyperactivity, conditioned place preference and postsynaptic dopamine receptor supersensitivity in mice. *Gen Pharmacol* 1998;30:783-789.
75. Kim HS, Jang CG, Oh KW et al. Effects of ginseng total saponin on morphine-induced hyperactivity and conditioned place preference in mice. *J Ethnopharmacol* 1998;60:33-42.
76. Kim HS, Kang JG, Rheu HM et al. Blockade by ginseng total saponin of the development of methamphetamine reverse tolerance and dopamine receptor supersensitivity in mice. *Planta Med* 1995;61:22-25.
77. Tokuyama S, Takahashi M. [Pharmacological and physiological effects of ginseng on actions induced by opioids and psychostimulants]. *Nippon Yakurigaku Zasshi* 2001;117:195-201.
78. Tsang D, Yeung HW, Tso WW, Peck H. Ginseng saponins: influence on neurotransmitter uptake in rat brain synaptosomes. *Planta Med* 1985;221-224.
79. Kimura T, Saunders PA, Kim HS et al. Interactions of ginsenosides with ligand-bindings of GABA(A) and GABA(B) receptors. *Gen Pharmacol* 1994;25:193-199.
80. Yuan CS, Attele AS, Wu JA, Liu D. Modulation of American ginseng on brainstem GABAergic effects in rats. *J Ethnopharmacol* 1998;62:215-222.
81. Stockley I. *Stockley's Drug Interactions*. 6th ed. London: Pharmaceutical Press; 2002.
82. Shader RI, Greenblatt DJ. Phenelzine and the dream machine—ramblings and reflections. *J Clin Psychopharmacol* 1985;5:65.
83. Treasure JE. Personal communication. In: Treasure JE, ed. Ashland, Ore; 2005:Natrol Inc Customer Support.
84. Shader RI, Greenblatt DJ. Bees, ginseng and MAOIs revisited. *J Clin Psychopharmacol* 1988;8:235.
85. Jones BD, Runikis AM. Interaction of ginseng with phenelzine. *J Clin Psychopharmacol* 1987;7:201-202.
86. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. *Arch Gen Psychiatry* 1991;48:1082-1088.
87. Siegel RK. Ginseng abuse syndrome: problems with the panacea. *JAMA* 1979;241:1614-1615.
88. Chen KJ. The effect and abuse syndrome of ginseng. *J Tradit Chin Med* 1981;1:69-72.

Citations and Reference Literature: Ginseng

89. Treasure JE. MEDLINE and the mainstream manufacture of misinformation. *J Am Herbalists Guild* 2006;6:50-56.
90. Scaglione F, Cattaneo G, Alessandria M, Cogo R. Efficacy and safety of the standardised Ginseng extract G115 for potentiating vaccination against the influenza syndrome and protection against the common cold [corrected]. *Drugs Exp Clin Res* 1996;22:65-72.
91. Rivera E, Daggfeldt A, Hu S. Ginseng extract in aluminum hydroxide adjuvanted vaccines improves the antibody response of pigs to porcine parvovirus and Erysipelothrix rhusiopathiae. *Vet Immunol Immunopathol* 2003;91:19-27.
92. Rivera E, Hu S, Concha C. Ginseng and aluminum hydroxide act synergistically as vaccine adjuvants. *Vaccine* 2003;21:1149-1157.
93. Takei M, Tachikawa E, Hasegawa H, Lee J-J. Dendritic cells maturation promoted by M1 and M4, end products of steroidal ginseng saponins metabolized in digestive tracts, drive a potent Th1 polarization. *Biochem Pharmacol* 2004;68:441-452.
94. Zhu M, Chan KW, Ng LS et al. Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. *J Pharm Pharmacol* 1999;51:175-180.
95. Jiang X, Williams KM, Liauw WS et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. *Br J Clin Pharmacol* 2004;57:592-599.
96. Yun YP, Do JH, Ko SR et al. Effects of Korean red ginseng and its mixed prescription on the high molecular weight dextran-induced blood stasis in rats and human platelet aggregation. *J Ethnopharmacol* 2001;77:259-264.
97. Park HJ, Rhee MH, Park KM et al. Effect of non-saponin fraction from Panax ginseng on cGMP and thromboxane A2 in human platelet aggregation. *J Ethnopharmacol* 1995;49:157-162.
98. Yuan CS, Wei G, Dey L et al. Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled trial. *Ann Intern Med* 2004;141:23-27.
99. Redman AR, Dickmann LJ, Kidd RS et al. CYP2C9 genetic polymorphisms and warfarin. *Clin Appl Thromb Hemost* 2004;10:149-154.
100. Takahashi H, Wilkinson GR, Caraco Y et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. *Clin Pharmacol Ther* 2003;73:253-263.
101. Kamali F, Khan TI, King BP et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. *Clin Pharmacol Ther* 2004;75:204-212.
102. Scordo MG, Pengo V, Spina E et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. *Clin Pharmacol Ther* 2002;72:702-710.
103. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. *Am J Health Syst Pharm* 1997;54:692-693.
104. Rosado MF. Thrombosis of a prosthetic aortic valve disclosing a hazardous interaction between warfarin and a commercial ginseng product. *Cardiology* 2003;99:111.
105. Becker BN, Greene J, Evanson J et al. Ginseng-induced diuretic resistance. *JAMA* 1996;276:606-607.
106. Xie JT, Wu JA, Mehendale S et al. Anti-hyperglycemic effect of the polysaccharides fraction from American ginseng berry extract in ob/ob mice. *Phytomedicine* 2004;11:182-187.
107. Xie JT, Mehendale SR, Wang A et al. American ginseng leaf: ginsenoside analysis and hypoglycemic activity. *Pharmacol Res* 2004;49:113-117.
108. Oshima Y, Konno C, Hikino H. Isolation and hypoglycemic activity of panaxans I, J, K and L, glycans of Panax ginseng roots. *J Ethnopharmacol* 1985;14:255-259.
109. Konno C, Murakami M, Oshima Y, Hikino H. Isolation and hypoglycemic activity of panaxans Q, R, S, T and U, glycans of Panax ginseng roots. *J Ethnopharmacol* 1985;14:69-74.
110. Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V. Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia. *Eur J Clin Nutr* 2003;57:243-248.
111. Sievenpiper JL, Arnason JT, Vidgen E et al. A systematic quantitative analysis of the literature of the high variability in ginseng (Panax spp.): should ginseng be trusted in diabetes? *Diabetes Care* 2004;27:839-840.
112. Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V. Decreasing, null and increasing effects of eight popular types of ginseng on acute postprandial glycemic indices in healthy humans: the role of ginsenosides. *J Am Coll Nutr* 2004;23:248-258.
113. Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V. Null and opposing effects of Asian ginseng (Panax ginseng C.A. Meyer) on acute glycemia: results of two acute dose escalation studies. *J Am Coll Nutr* 2003;22:524-532.